Veritas' Proceeding to Build State-of-the-Art Cannabis Cultivation Facility
Vancouver, British Columbia--(Newsfile Corp. - July 10, 2017) - Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (Frankfurt: 2VP) is pleased to announce that it is preparing to begin construction of a state-of-the-art cannabis growing facility upon receiving Health Canada's license under Access to Cannabis for Medical Purposes Regulations (ACMPR). Veritas Pharma, through its subsidiary Sechelt Organic Marijuana Corp., has initiated the tendering process and is awaiting bids for the construction of...
2017-07-10 5:08 AM EDT
Veritas Pharma Places Final Payment in Trust for the Acquisition of Cannevert Therapeutics
Vancouver, British Columbia--(Newsfile Corp. - January 25, 2017) - Veritas Pharma Inc. (CSE: VRT) (OTC Pink: VRTHF) (FSE: 2VP), an emerging discovery and IP development company, has announced that it has placed its final payment of $250,000 to Cannevert Therapeutics Ltd. (CTL) (scheduled for May 1st, 2017) into a trust account. The completion of this payment will bring Veritas' investment in CTL up to $1,500,000 granting an 80% ownership of CTL, with an option to purchase the additional...
2017-01-25 5:23 PM EST
Veritas Pharma Advances Fifth of Six Equal Payments to Cannevert Therapeutics Ltd.
Vancouver, British Columbia--(Newsfile Corp. - January 23, 2017) - Veritas Pharma Inc. (CSE: VRT) (OTC Pink: VRTHF) (FSE: 2VP), an emerging discovery and IP development company, is pleased to announce that it has completed its second to last payment of $250,000 to Cannevert Therapeutics Ltd. (CTL). This latest installment brings Veritas' total investment in CTL to $1,250,000. An additional $250,000 needs to be paid by May 1st, 2017. The final payment will grant Veritas Pharma an 80% ownership...
2017-01-23 6:04 PM EST
Veritas Receives Listing on the Xetra(R) (Frankfurt, Germany) Trading Venue
Vancouver, British Columbia--(Newsfile Corp. - December 7, 2016) - Veritas Pharma Inc. (CSE: VRT) (OTC Pink: VRTHF) (FSE: 2VP), an emerging discovery and IP development company, is pleased to announce that as of December 7th, 2016, its common shares are accepted for continuous trading on the electronic trading platform XETRA® on the Frankfurt Exchange under the symbol 2VP. Veritas Pharma's management expects that a listing through Xetra® will provide higher liquidity and more efficient market...
2016-12-07 6:02 PM EST
Report on Canada's Marijuana Legalization is Anticipated to be Released This Week
Vancouver, British Columbia--(Newsfile Corp. - November 29, 2016) - Veritas Pharma Inc. (CSE: VRT) (OTC Pink: VRTHF) (FSE: 2VP) ("VRT" or the "Company") is eagerly awaiting the report of the Task Force on Marijuana Legalization to be delivered by its Chair, Anne McLellan to the Canadian Federal Cabinet by this Wednesday. The Company expects that the report will provide the Government's roadmap on implementing a legal recreational marijuana market. "Guidance is expected on a minimum age for...
2016-11-29 8:36 AM EST
Veritas Pharma Inc. Management Discussion and Analysis Amendment and Restatement
Vancouver, British Columbia--(Newsfile Corp. - November 25, 2016) - Veritas Pharma Inc. (CSE: VRT) (OTC Pink: VRTHF) (FSE: 2VP), ("Veritas" or the "Company"), as a result of a review by the British Columbia Securities Commission, is issuing the following press release to clarify our disclosure. We have amended and restated our Management Discussion and Analysis ("MD&A") to more fully disclose the effect of the advances by the Company to CTL. The MD&A has also been updated to increase the...
2016-11-25 4:05 PM EST
Veritas Pharma Enters into Agreement to Secure ACMPR License and Cannabis Growing Facility
Vancouver, British Columbia--(Newsfile Corp. - November 21, 2016) - Veritas Pharma Inc. (CSE: VRT) (OTC Pink: VRTHF) (FSE: 2VP), ("Veritas" or the "Company"), an emerging-stage pharmaceutical and IP development company, is pleased to announce that it has signed a Letter of Intent ("LOI") with Sechelt Organic Marijuana Inc. ("Privco"), whereby Veritas has been granted the exclusive option to acquire 100% ownership of PrivCo (the "Transaction"), subject to certain terms and conditions...
2016-11-21 8:00 AM EST
Veritas Announces an Expansion to the Private Placement and Engages European Healthcare Capital
Vancouver, British Columbia--(Newsfile Corp. - November 16, 2016) - Veritas Pharma Inc. (CSE: VRT) (OTC Pink: VRTHF) (FSE: 2VP), an emerging discovery and IP development company, has expanded the private placement offering announced on September 16th and has engaged the European Healthcare Capital ("EHC") to grow investor awareness of medical marijuana industry. The expansion to the private placement will be for an additional one-month period from the date of this announcement and will expand...
2016-11-16 7:41 AM EST
Veritas Pharma Inc. Management Discussion and Analysis Amendment and Restatement
Vancouver, British Columbia--(Newsfile Corp. - November 9, 2016) - Veritas Pharma Inc. (CSE: VRT) (OTC Pink: VRTHF) (FSE: 2VP), ("Veritas" or the "Company"), as a result of a review by the British Columbia Securities Commission, is issuing the following press release to clarify our disclosure. We have amended and restated our Management Discussion and Analysis ("MD&A") to more fully disclose the effect of the advances by the Company to CTL. The MD&A has also been updated to increase the...
2016-11-09 10:51 PM EST
Veritas Approves Issue of Stock Options
Vancouver, British Columbia--(Newsfile Corp. - September 6, 2016) - Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FSE: 2VP) ("VRT" or the "Company"), an early stage pharmaceutical company developing innovative medicinal cannabis cultivars for specific disease conditions such as chronic pain, emesis (nausea/vomiting), and epilepsy, today announced that 1,000,000 stock options have been issued; 200,000 each to its two new directors; Dr. Don Carlow and Mr. Matthew Hamilton; as well as 300,000 to...
2016-09-06 9:00 AM EDT
Veritas Pharma Inc. Exclusive Partner Qualifies For Non-Dilutive Grant
Vancouver, British Columbia--(Newsfile Corp. - August 23, 2016) - Veritas Pharma Inc. (CSE: VRT) (OTC Pink: VRTHF) (FSE: 2VP) ("Veritas" or the "Company"), an emerging discovery and IP development company, has announced that Cannevert Therapeutics Ltd., the Company's exclusive partner and high-level R&D arm, has been awarded a research grant through Mitacs Inc. for research and development work related to the discovery of new cannabis strains for specific disease conditions. Mitacs is a...
2016-08-23 8:00 AM EDT